Author
Gergely L. Lukács
Recent research
- Health & MedicineOpen access
Triple potentiator combinations increase the functional correction of several CFTR gating mutants
The Trikafta drug combination, comprising the corrector tezacaftor (VX-661), the potentiator ivacaftor (VX-770) and the dual corrector/potentiator elexacaftor (VX-445), has been FDA-approved for treatment of cystic fibrosis caused by ~300 cystic fibrosis transmembrane conductance...